ractitioner's Docket No. U 012473-1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Antonio LOPEZ-CABRERA, et al.

Serial No.:

09/660,022

Group No.:

1615

Examiner:

Filed: September 12, 2000

Ware, T.

For:

SOLID ORAL PHARMACEUTICAL FORMULATION OF MODIFIED RELEASE THAT

CONTAINS AND ACID LABILE BENZIMIDAZOLE COMPOUND

RESPONSE UNDER 37 C.F.R. 1.116 **EXPEDITED PROCEDURE EXAMINING GROUP** 1615

Box AF

Assistant Commissioner for Patents

Washington, DC 20231

To take advantage of the expedited procedure the envelope in which this paper is mailed must be addressed as shown and must also be marked "Box AF" in the lower left hand comer. Alternatively, this paper can be hand carried to the particular Examining Group or other area of the Office in which the application is pending, in which case any envelope in which this paper is place must be marked as in the bold type box above. Notice of September 20, 1985 (1059 O.G. 20-21).

AMENDMENT OR RESPONSE AFTER FINAL REJECTION-FIRST PAGE

CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10*

(When using Express Mail, the Express Mail label number is mandatory: Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

-	⊠	deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.		
		37 C.F.R. 1.8(a)		37 C.F.R. 1.10*
	×	with sufficient postage as first class mail.		as "Express Mail Post Office to Address" Mailing Label No. (mandatory)
		TRANSMISSION		(,
10/29/2002	□ TGEDANU1	transmitted by facsimile to the Patent and Trademark Office		
02 FC:1401		320.00 OP	Signati	ire
•	Date:	October 22, 2002	JANE	T I. CORD
			(type or	print name of person certifying)

*WARNING:

Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).

"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Amendment or Response after Final Rejection-First Page) 9-20.1